HERTFORDSHIRE, England and
PITTSBURGH, June 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq:
MYL) today commented on the ruling by the U.S. Court of Appeals for
the Federal Circuit, which again has found Teva's U.S. Patent No.
5,800,808 ("the '808 patent") for Copaxone® to be invalid as
indefinite.
Mylan CEO Heather Bresch said,
"We have stated all along that the '808 patent on Copaxone® is
invalid and are gratified that the Federal Circuit Court of Appeals
has agreed and put this matter to rest. We continue to remain very
confident in our application for our generic version of Copaxone
and look forward to bringing our product to market upon approval
from the U.S. Food and Drug Administration.
"Further, we believe this ruling underscores concerns with
Teva's ongoing financial prospects, as Teva's Copaxone franchise
has historically been its largest and most significant revenue
driver."
This press release includes statements that constitute
"forward-looking statements," including with regard to litigation,
product approvals and sales of products. These statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because such statements inherently
involve risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to: strategies by
competitors or other third parties to delay or prevent product
introductions; risks inherent in legal and regulatory processes;
uncertainties and other matters beyond the control of management;
and the other risks detailed in the company's filings with the
Securities and Exchange Commission. The company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of around 1,400 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral
therapies, upon which nearly 50% of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active
pharmaceutical ingredient manufacturers and currently market
products in about 145 countries and territories. Our workforce of
approximately 30,000 people is dedicated to creating better health
for a better world, one person at a time. Learn more at
mylan.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/us-court-of-appeals-for-the-federal-circuit-finds-tevas-808-copaxone-patent-invalid-300101464.html
SOURCE Mylan N.V.